Meta Information

ID:inclisiran

Name:Inclisiran

Schema Version:1.5

Alternate Names

• Leqvio

Intervention Type

therapeutic_agent

Expected Cost Mean

Low Cost:

0

High Cost:

6500

Cost Type:

annual

Description:

Annual cost for two injections; may be covered by insurance for specific indications.

Summary

Inclisiran is a small interfering RNA (siRNA) that prevents the production of the PCSK9 protein in the liver. By silencing the PCSK9 gene, it dramatically increases the liver's ability to clear LDL cholesterol from the blood. Reducing cumulative, lifelong exposure to LDL-C is a primary strategy for preventing atherosclerotic cardiovascular disease (ASCVD), a major driver of age-related morbidity and mortality.

Purpose

Dramatically lowers LDL cholesterol by silencing the PCSK9 gene.

Card Summary

A twice-yearly injection that silences the PCSK9 gene to profoundly lower LDL cholesterol.

Drug Class

pcsk9_inhibitor_sirna

Drugs In Class

Empty Array

Impact

Score:

7.8

Justification:

Profound and sustained reduction of LDL-C, a key driver of atherosclerosis.

Evidence

Grade:

A

Score:

9.5

Justification:

Multiple large-scale human RCTs (ORION trials) confirm robust LDL-C reduction.

Safety

Score:

4.5

Justification:

Generally well-tolerated; primary side effects are mild injection site reactions.

Flags

• Injection site reactions (pain, redness, rash) are the most common side effects.
• Long-term cardiovascular outcomes data is still being collected (ORION-4 trial).
• High cost and insurance hurdles can be significant barriers to access.
• Currently approved for patients with clinical ASCVD or heterozygous familial hypercholesterolemia.

Verdict

A powerful, long-acting tool for profound LDL cholesterol reduction.

Created

2026-04-27T00:48:02.920844Z

Model

Gemini 3.1 Pro (High)

Delivery

Route:

subcutaneous_injection

Scope:

• systemic

Indication

Focus:

disease_treatment

Description:

Inclisiran is a small interfering RNA (siRNA) that prevents the production of the PCSK9 protein in the liver. By silencing the PCSK9 gene, it dramatically increases the liver's ability to clear LDL ch...

Typical Protocol

• A single 284mg subcutaneous injection administered twice per year after initial loading doses.